ABUS Stock Price History and Quote Analysis: Insights for Investors
Arbutus Biopharma Corporation
Stock Price Today
Arbutus Biopharma Corporation (ABUS) stock surged +1.56%, trading at $4.56 on NASDAQ, up from the previous close of $4.49. The stock opened at $4.49, fluctuating between $4.36 and $4.60 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Company Information
| Employees | 73 |
| Beta | 1.91 |
| Sales or Revenue | $18.14M |
| 5Y Sales Change% | 0.025% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock price is $4.56 in the last trading session. During the trading session, ABUS stock reached the peak price of $4.60 while $4.36 was the lowest point it dropped to. The percentage change in ABUS stock occurred in the recent session was 1.56% while the dollar amount for the price change in ABUS stock was $0.07.
The NASDAQ listed ABUS is part of Biotechnology industry that operates in the broader Healthcare sector. Arbutus Biopharma Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.
Sec.
Mr. J. Christopher Naftzger
Gen. Counsel & Chief Compliance Officer
Mr. William H. Collier
Pres, Chief Executive Officer & Director
Mr. David C. Hastings CPA
Chief Financial Officer & Chief Accounting Officer
Dr. Elizabeth Howard
Executive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.
Dr. Michael J. Sofia Ph.D.
Chief Scientific Officer
Ms. Lisa M. Caperelli
Vice President of Investor Relations
Dr. Gaston Picchio Ph.D.
Chief Devel. Officer
Mr. Michael J. McElhaugh
Chief Operating Officer & Chief Bus. Officer
Dr. Elizabeth Howard J.D., Ph.D.
Executive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.
Mr. Christopher Naftzger
Gen. Counsel & Chief Compliance Officer
Dr. Karen Sims M.D., Ph.D.
Chief Medical Officer
Karen Sims
Vice President of Clinical Devel.
Mr. J. Christopher Naftzger BA, Esq., J.D.
Gen. Counsel & Chief Compliance Officer
ABUS's closing price is 169.82% higher than its 52-week low of $1.69 where as its distance from 52-week high of $4.72 is -3.39%.
Number of ABUS employees currently stands at 73.
Official Website of ABUS is: https://www.arbutusbio.com
ABUS could be contacted at phone 267 469 0914 and can also be accessed through its website. ABUS operates from 701 Veterans Circle, Warminster, PA 18974, United States.
ABUS stock volume for the day was 1.63M shares. The average number of ABUS shares traded daily for last 3 months was 1.03M.
The market value of ABUS currently stands at $860.85M with its latest stock price at $4.56 and 188.78M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com